MicroRNA-nanoparticles against cancer: Opportunities and challenges for personalized medicine.
MT: Non-coding RNAs
cancer
colorectal cancer
miRNAs
nanomedicine
nanoparticles
theranostics
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
13 Jun 2023
13 Jun 2023
Historique:
medline:
2
5
2023
pubmed:
2
5
2023
entrez:
2
5
2023
Statut:
epublish
Résumé
Micro-RNAs (miRNAs) control gene expression at the post-transcriptional level and are widely involved in carcinogenesis, playing a role as both oncogenes and tumor suppressors. MiRNAs act as potent therapeutic weapon in cancer, but their potential therapeutic use is limited by the off-target effect due to their nonspecific distribution in normal tissues. The encapsulation of miRNAs in nanostructured carriers allows targeted effects aimed to destroy cancer cells, without affecting healthy tissues. Due to their small size and the optimal surface/size ratio, nanoparticles (NPs) envelop, protect, and release miRNAs, representing a promising strategy in cancer treatment. In the present review, we discuss the latest advances in the field of miRNA-encapsulating NPs in cancer, focusing on colorectal cancer and its metastatic forms, one of the most common malignancies worldwide.
Identifiants
pubmed: 37128277
doi: 10.1016/j.omtn.2023.03.021
pii: S2162-2531(23)00080-X
pmc: PMC10148042
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
371-384Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Epigenomes. 2023 Jan 10;7(1):
pubmed: 36648863
ACS Biomater Sci Eng. 2019 Nov 11;5(11):6036-6045
pubmed: 33405725
EMBO J. 2023 Jan 16;42(2):e111673
pubmed: 36514940
RSC Adv. 2020 Jan 23;10(7):3967-3977
pubmed: 35492632
Mol Biol Rep. 2021 Oct;48(10):6805-6820
pubmed: 34468912
Cancer Sci. 2021 Oct;112(10):4270-4280
pubmed: 34270831
Front Oncol. 2020 Jul 17;10:1034
pubmed: 32766131
Semin Cancer Biol. 2021 Feb;69:293-306
pubmed: 31260733
Semin Cell Dev Biol. 2018 Jun;78:37-50
pubmed: 28765094
Curr Drug Metab. 2022;23(10):800-817
pubmed: 35430962
Oncol Lett. 2021 Jun;21(6):489
pubmed: 33968205
Lasers Med Sci. 2023 Jan 11;38(1):37
pubmed: 36627516
Int J Nanomedicine. 2020 Aug 24;15:6295-6310
pubmed: 32943863
Front Bioeng Biotechnol. 2022 Oct 17;10:1013541
pubmed: 36324898
Chem Commun (Camb). 2018 Nov 8;54(90):12762-12765
pubmed: 30370905
Front Cell Dev Biol. 2021 Jan 15;8:604869
pubmed: 33520987
Nanoscale. 2019 May 16;11(19):9661-9678
pubmed: 31065660
Oncogene. 2021 Jul;40(28):4695-4708
pubmed: 34140641
Drug Discov Today. 2017 Feb;22(2):424-432
pubmed: 27815139
Nat Rev Clin Oncol. 2021 Aug;18(8):506-525
pubmed: 33864051
Drug Deliv. 2022 Dec;29(1):1712-1725
pubmed: 35635307
Front Chem. 2021 Nov 08;9:789934
pubmed: 34820358
Ann Transl Med. 2022 Dec;10(24):1374
pubmed: 36660663
Front Oncol. 2021 May 04;11:638537
pubmed: 34017681
Diagnostics (Basel). 2021 Feb 19;11(2):
pubmed: 33669508
Mol Med Rep. 2021 Aug;24(2):
pubmed: 34109432
World J Surg Oncol. 2021 Apr 13;19(1):117
pubmed: 33849554
Int J Mol Sci. 2022 Feb 01;23(3):
pubmed: 35163607
Futur J Pharm Sci. 2022;8(1):12
pubmed: 35071609
Polymers (Basel). 2022 Jun 27;14(13):
pubmed: 35808648
Signal Transduct Target Ther. 2023 Jan 27;8(1):37
pubmed: 36702817
Cancer Sci. 2020 May;111(5):1528-1541
pubmed: 32073706
Ann Transl Med. 2021 May;9(9):747
pubmed: 34268360
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Anticancer Res. 2021 Aug;41(8):3899-3904
pubmed: 34281852
Pathol Oncol Res. 2022 Oct 18;28:1610699
pubmed: 36330052
J Nanobiotechnology. 2021 Oct 30;19(1):354
pubmed: 34717658
J Cancer Res Ther. 2022 Jul-Sep;18(4):921-926
pubmed: 36149141
World J Gastroenterol. 2022 Dec 14;28(46):6497-6511
pubmed: 36569271
Int J Mol Sci. 2022 Sep 29;23(19):
pubmed: 36232799
Mol Immunol. 2023 Mar;155:58-68
pubmed: 36709645
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396561
Int J Pharm. 2023 Feb 5;632:122570
pubmed: 36587775
Afr Health Sci. 2020 Sep;20(3):1283-1291
pubmed: 33402976
Theranostics. 2021 Jan 1;11(5):2475-2489
pubmed: 33500737
Asian J Pharm Sci. 2022 Aug;17(5):751-766
pubmed: 36382309
Biomater Sci. 2021 Sep 28;9(19):6528-6541
pubmed: 34582541
Pharmaceutics. 2023 Jan 08;15(1):
pubmed: 36678844
Cell Rep. 2018 Apr 3;23(1):100-111
pubmed: 29617652
Adv Pharm Bull. 2021 Feb;11(2):233-247
pubmed: 33880345
Cell Stress. 2019 Jul 31;3(8):267-279
pubmed: 31440741
Pharm Res. 2023 Jan;40(1):27-46
pubmed: 36600047
Int J Pharm. 2020 Jun 30;584:119394
pubmed: 32407940
Int J Hyperthermia. 2017 May;33(3):327-335
pubmed: 27701929
Cancer Immunol Immunother. 2018 Sep;67(9):1461-1472
pubmed: 30014244
Chem Biol Interact. 2018 Nov 1;295:1-12
pubmed: 30048623
CA Cancer J Clin. 2022 Jul;72(4):372-401
pubmed: 35472088
Theranostics. 2020 Feb 18;10(8):3594-3611
pubmed: 32206110
Cancers (Basel). 2021 Apr 24;13(9):
pubmed: 33923200
J Cell Physiol. 2020 Sep;235(9):6218-6229
pubmed: 32091625
Biosci Rep. 2023 Feb 27;43(2):
pubmed: 36630532
Beilstein J Nanotechnol. 2020 Jul 27;11:1092-1109
pubmed: 32802712
Ann Med. 2021 Dec;53(1):87-102
pubmed: 33108223
Anal Sci. 2022 Mar;38(3):497-504
pubmed: 35359267
J Biomed Nanotechnol. 2019 Nov 1;15(11):2240-2250
pubmed: 31847938
Methods Mol Biol. 2018;1682:3-16
pubmed: 29039088
Life Sci. 2021 Nov 15;285:119937
pubmed: 34508764
J Cell Mol Med. 2021 Jul;25(14):6874-6886
pubmed: 34101338
Acc Chem Res. 2019 Sep 17;52(9):2445-2461
pubmed: 31424909
Bioorg Med Chem Lett. 2013 Jan 15;23(2):565-8
pubmed: 23232055
Clin Epigenetics. 2019 Feb 11;11(1):25
pubmed: 30744689
Sci Rep. 2022 Mar 18;12(1):4713
pubmed: 35304514
Biomed Pharmacother. 2019 Jan;109:902-909
pubmed: 30551544
ACS Biomater Sci Eng. 2022 Dec 12;8(12):5210-5220
pubmed: 36446128
J Biomed Nanotechnol. 2018 May 1;14(5):946-958
pubmed: 29883564
Front Mol Biosci. 2022 Jan 03;8:799060
pubmed: 35047559
Semin Cancer Biol. 2022 Nov;86(Pt 3):199-206
pubmed: 35248730
BMC Cancer. 2021 Sep 3;21(1):989
pubmed: 34479528
Semin Cancer Biol. 2022 Nov;86(Pt 2):358-375
pubmed: 35623562
Cells. 2019 Nov 18;8(11):
pubmed: 31752117
Cancer Lett. 2019 Jun 28;452:66-70
pubmed: 30902563
Cancers (Basel). 2020 Dec 15;12(12):
pubmed: 33333816
Oncotarget. 2017 Sep 26;8(54):92018-92031
pubmed: 29190894
Cancer Immunol Immunother. 2021 Nov;70(11):3081-3091
pubmed: 33751208
Cancer Manag Res. 2021 Mar 23;13:2717-2731
pubmed: 33790646
Cells. 2021 Nov 09;10(11):
pubmed: 34831320
J Drug Target. 2023 Mar;31(3):296-309
pubmed: 36398476
Br J Cancer. 2022 Jul;127(1):156-162
pubmed: 35318434
Int J Mol Sci. 2021 Jul 21;22(15):
pubmed: 34360564
Semin Oncol Nurs. 2019 Feb;35(1):58-78
pubmed: 30665732
Commun Biol. 2021 Jun 16;4(1):747
pubmed: 34135460
Cancer Rep (Hoboken). 2022 Nov;5(11):e1612
pubmed: 35243812
Colloids Surf B Biointerfaces. 2023 Feb;222:113131
pubmed: 36646005
BMC Genomics. 2023 Mar 2;24(1):96
pubmed: 36864382
Bioengineered. 2021 Dec;12(1):6343-6353
pubmed: 34506231
Exp Biol Med (Maywood). 2022 Jun;247(11):898-909
pubmed: 34904882
J Cancer Res Ther. 2022 Dec;18(Supplement):S383-S390
pubmed: 36510992
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Expert Opin Drug Deliv. 2009 Sep;6(9):883-95
pubmed: 19637985
Phys Rev Lett. 2007 Oct 26;99(17):179703; author reply 179704
pubmed: 17995379
Expert Opin Drug Deliv. 2021 Sep;18(9):1169-1192
pubmed: 33567909
Oncol Lett. 2018 Apr;15(4):4781-4788
pubmed: 29552117
Acc Chem Res. 2020 Oct 20;53(10):2094-2105
pubmed: 33017150
J Control Release. 2019 Nov 10;313:80-95
pubmed: 31622695
Cell Signal. 2023 Jan;101:110517
pubmed: 36332797
Front Oncol. 2021 Oct 19;11:738144
pubmed: 34737955
ACS Nano. 2018 Jun 26;12(6):5121-5129
pubmed: 29771487
Cells. 2022 Sep 07;11(18):
pubmed: 36139366
J Zhejiang Univ Sci B. 2020 Sept.;21(9):673-689
pubmed: 32893525
Pharm Res. 2009 May;26(5):1025-58
pubmed: 19107579
Mater Sci Eng C Mater Biol Appl. 2019 May;98:1252-1276
pubmed: 30813007
Mol Ther. 2021 Sep 1;29(9):2723-2736
pubmed: 33905821
Bioconjug Chem. 2022 Sep 21;33(9):1698-1706
pubmed: 35960898
Adv Pharm Bull. 2022 Aug;12(4):772-779
pubmed: 36415636
J Cancer. 2019 Oct 15;10(24):6037-6047
pubmed: 31762813
Semin Cancer Biol. 2022 Nov;86(Pt 2):1-13
pubmed: 36028154
Int J Biol Macromol. 2023 Apr 1;233:123273
pubmed: 36646349
J Pers Med. 2021 Aug 06;11(8):
pubmed: 34442415
Genes (Basel). 2021 Apr 09;12(4):
pubmed: 33918859
Biomater Sci. 2019 Jun 25;7(7):2740-2748
pubmed: 30994642
Cancers (Basel). 2021 Mar 24;13(7):
pubmed: 33804927
J Nanobiotechnology. 2020 Jan 9;18(1):10
pubmed: 31918721
FEBS Open Bio. 2020 Jan;10(1):168-175
pubmed: 31769193
Mol Biol Rep. 2019 Aug;46(4):4175-4183
pubmed: 31123908
Nanomedicine (Lond). 2020 Apr;15(10):969-980
pubmed: 32223518
Cancer Cell Int. 2021 Jul 7;21(1):358
pubmed: 34315491
Immunotherapy. 2018 Sep;10(13):1175-1188
pubmed: 30236026
BMC Complement Med Ther. 2022 Dec 27;22(1):340
pubmed: 36575448
Cell Death Dis. 2023 Jan 26;14(1):62
pubmed: 36702852
Transl Oncol. 2021 Feb;14(2):101000
pubmed: 33352502
Int Immunopharmacol. 2021 Mar;92:107355
pubmed: 33429333
Mater Sci Eng C Mater Biol Appl. 2019 Apr;97:913-931
pubmed: 30678981
Mol Pharm. 2022 Dec 5;19(12):4588-4600
pubmed: 35731922
J Control Release. 2022 Feb;342:241-279
pubmed: 35016918
Pharm Nanotechnol. 2022 Jun 06;:
pubmed: 35670355
Molecules. 2020 May 08;25(9):
pubmed: 32397080
BMC Cancer. 2023 Jan 16;23(1):54
pubmed: 36647053
Int J Mol Sci. 2022 Jan 30;23(3):
pubmed: 35163550
Cells. 2019 Dec 20;9(1):
pubmed: 31861937
Int J Nanomedicine. 2022 Dec 28;17:6687-6705
pubmed: 36597434
J Cell Physiol. 2020 Mar;235(3):1962-1972
pubmed: 31441032
Adv Healthc Mater. 2023 Jan;12(6):e2202672
pubmed: 36459471
J Control Release. 2018 Apr 10;275:85-91
pubmed: 29421609
BMC Cancer. 2022 Jul 30;22(1):835
pubmed: 35907803